MCP Adds Second Product To Multi-Year Contract Manufacturing Agreement

MCP Pharmaceuticals Adds Second Product To Multi-Year Contract Manufacturing Agreement

PARSIPPANY, NJ February 29, 2012 — MCP Pharmaceuticals, a provider of global contract manufacturing services for sterile products added a second product to an established multi-year contract with an undisclosed pharmaceutical company. MCP will be responsible for manufacturing and supply of an injectable anesthetic agent.

Stuart Hinchen president and CEO of MCP stated, “We are very pleased that MCP was chosen again by this well- established customer, as it speaks to their satisfaction with our work. We recently successfully completed an FDA (CBER) Pre-Approval Inspection in support of a biologic product launch for another long-term contract customer. MCP’s approach in meeting contract customer needs in a timely fashion creates an environment where customers are confident bringing additional manufacturing needs to us. Customers also rely on our extensive experience working with products throughout their life cycle which results in continuity of supply and program efficiencies.”

Hinchen noted, “MCP’s cGMP compliance record and established infrastructure combined with a broad and deep experience base have established a foundation that supports growth with both new and long-term customers.”

MCP’s Rochester, Michigan manufacturing site has a solid history of manufacturing a broad range of sterile product types including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics.

About MCP Pharmaceuticals, LLC

MCP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile products including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics for large and small pharmaceutical and biotech organizations. MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse.

The production facility utilizes three high-speed filling lines, a clinical filling line and four lyophilizers. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development. MCP has the capability to manufacture small-scale clinical through large-scale commercial products. MCP employs more than 370 staff in the USA in its manufacturing, product development, regulatory, sales and marketing and corporate areas. For more information, please visit jhppharma.com.

Additional Press Releases

04/17/13

MCP Pharmaceuticals To Produce Supplies of Biologic Drug Product For Late-Phase Clinical Trials

Webpage | PDF Format

12/31/12

MCP Pharmaceuticals Acquired By Warburg Pincus

Webpage | PDF Format

09/19/12

MCP Pharmaceuticals To Produce Lyophilized Biologic for International Late-Phase Clinical Trials

Webpage | PDF Format

06/07/12

MCP Pharmaceuticals Launches Generic Division